The study of brain tumors using real-time imaging of the brain in live disease models is critical for elucidating disease mechanisms and developing novel treatment strategies. Such research requires full characterization of healthy and disease phenotypes using a multi-omics analysis, as described in this blog.

Technology Networks recently spoke with Stephen Williams, CMO at biotechnology company SomaLogic, to learn more about research progress in the proteomics space and the technology that has enabled it.

Technology Networks spoke with GenapSys to learn more about the sequencer which is "100x smaller and less expensive than legacy high-throughput sequencers" and how it can be applied to study the Coronavirus.

At the beginning of the year, direct-to-consumer (DTC) genetic testing company 23andMe announced that they have generated a bispecific antibody that blocks the IL-36 cytokine family associated with multiple inflammatory diseases. Technology Networks spoke with Christine Pai from 23andMe to find out more.

Many biotherapeutic drugs such as recombinant antibodies are manufactured utilizing host cells, a common example being Chinese hamster ovary (CHO) cells. A key factor for consideration in this process is the growth and viability of these cells – ultimately this influences the quality and quantity of the biotherapeutic product. Technology Networks spoke with Nicole Wellens, Global Product Manager for BioTherapeutics Media, Lonza to learn more about the new feed and how it has been developed.

The highly complex process of whole genome sequencing comes with a high cost of error. One pipetting or mixing mistake can lead to costly errors downstream. When working with multiple samples, error-free sample handling and proper mixing becomes even more critical. The first step in the process to prepare the sample for sequencing, library prep, is a vital step that, if not done correctly, can lead to flawed data and costly delays.

Many clinical trials fail due to lack of efficacy. But while some of this may be due to poor target selection during the drug discovery process, it’s becoming increasingly clear that only certain patients respond to treatments. So how exactly does precision medicine increase the likelihood of success in clinical trials?

Introduced back in March 2019, Cell Mentor^TM is an online educational resource for biology students and researchers, created by Cell Signaling Technology and Cell Press. To open the resource up to even more scientists, a Chinese version of the site was recently launched.

We recently spoke to Elena Sukhacheva, Director Medical and Scientific Affairs at Beckman Coulter, to learn about some of the challenges of diagnosing sepsis early, and how measuring Monocyte Distribution Width can be used as a sepsis biomarker to aid the process.

With constant conversations examining the potential of CRISPR technology, it can be hard to focus on what has been achieved since 2012 and to look toward the future to determine what may be achievable both in the near – and longer – term.